登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C17H27N3O4S
化学文摘社编号:
分子量:
369.48
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
275-831-7
MDL number:
产品名称
氨磺必利, ≥98% (HPLC)
InChI
1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)
InChI key
NTJOBXMMWNYJFB-UHFFFAOYSA-N
SMILES string
O=C(NCC1CCCN1CC)C2=CC(S(=O)(CC)=O)=C(N)C=C2OC
assay
≥98% (HPLC)
form
powder
storage condition
desiccated, protect from light
color
white
originator
Sanofi Aventis
storage temp.
2-8°C
Quality Level
Gene Information
正在寻找类似产品? 访问 产品对比指南
Application
Amisulpride has been used as a dopamine receptor inhibitor to study its effects on diabetic bone abnormalities in mice.
Biochem/physiol Actions
Amisulpride is a highly selective D2/D3 dopamine receptor antagonist and atypical antipsychotic.
Amisulpride is a substituted benzamide derivative. It has a higher affinity towards dopamine receptors in limbic structures than the striatal structures. Amisulpride has a therapeutic effect against schizophrenia.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
J Peuskens et al.
Psychiatry research, 88(2), 107-117 (2000-01-06)
Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia. The study was double-blind and involved 228 patients allocated, after a 3-6-day wash-out period
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens J, et al.
Psychiatry Research, 88(2), 107-117 (1999)
Impaired gastric hormone regulation of osteoblasts and lysyl oxidase drives bone disease in diabetes mellitus
Daley E J, et al.
JBMR plus, 3(10), e10212-e10212 (2019)
Eileen J Daley et al.
JBMR plus, 3(10), e10212-e10212 (2019-11-07)
Diabetic bone disease is a complication of type I and type II diabetes, both of which are increasing in the United States and elsewhere. Increased hip and foot fracture rates do not correlate well with changes in bone mineral density
Ann Mortimer et al.
International clinical psychopharmacology, 19(2), 63-69 (2004-04-13)
Atypical antipsychotics offer advantages over earlier drugs for the treatment of schizophrenia, although few data exist on the relative merits of different atypical antipsychotics. A multicentre, double-blind, randomized trial was performed to compare amisulpride and olanzapine in the treatment of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持